Clinical trial · Interventional
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
Explorative Investigations on the Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or extracorporeal photochemotherapy (photopheresis). The study will address whether and how photo(chemo)therapy affects specific biologic pathways in different skin disorders and search for predictive biomarkers.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Eczema | — | UNRESOLVED | — |
| Graft Vs Host Disease | — | UNRESOLVED | — |
| Lichen Planus | — | UNRESOLVED | — |
| Lymphoproliferative Disorders | — | UNRESOLVED | — |
| Mastocytosis | Mastocytosis | ONTOLOGY_EXACT | 0.98 |
| Polymorphic Light Eruption | — | UNRESOLVED | — |
| Prurigo | — | UNRESOLVED | — |
| Pruritus | — | UNRESOLVED | — |
| Psoriasis | — | UNRESOLVED | — |
| Vitiligo | — | UNRESOLVED |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Photo(chemo)therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Correlation of soluble factors in the serum with clinical response, as measured by disease severity
- timeFrame
- Day 14 to 0; week 4; week 8-12; week 12-16 (or month 6-12 for photopheresis)
- description
- Serum levels of cytokines, chemokine and other factors, as measured in pg/ml, will be correlated to the clinical response to treatment at the time points specified below to identify potential predictive biomarkers. Disease-specific scores such as PASI, mSWAT, SCORAD, scleroderma score and VAS pruritus scores will be used depending on the condition to carry-out correlation analysis, comparing the change from baseline to end of observation.
- measure
- Correlation of cellular markers of peripheral lymphocytes with clinical response, as measured by disease severity
- timeFrame
- Day 14 to 0; week 4; week 8-12; week 12-16 (or month 6-12 for photopheresis)
- description
- Expression of cellular markers including CD (cluster of differentiation) 1a, CD3, CD4, CD8, CD11c, CD25, CD45, CD56, CD68, CD103, CD163, FoxP3, as measured by flow cytometry will be correlated to the clinical response to treatment at the time points specified below to identify potential predictive biomarkers. Disease-specific scores such as PASI, mSWAT, SCORAD, scleroderma score and VAS pruritus scores will be used depending on the condition to carry-out correlation analysis, comparing the change from baseline to end of observation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Skin disorder to be treated with photo(chemo)therapy Exclusion Criteria: * Pregnancy and breastfeeding * Poor general health status
References
Publications (0)
Data not yet available